ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1953

Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis

Ana Márquez1, Francisco David Carmona2, Maria C. Cid3, José Hernández-Rodríguez3, Roser Solans4, Marc Ramentol4, Santos Castañeda5, Jose A. Miranda-Filloy6, Inmaculada C. Morado7, Javier Narváez8, Eugenio De Miguel9, Bernardo Sopeña10, Jordi Monfort11, Maria Jesus Garcia-Villanueva12, Norberto Ortego-Centeno13, Miguel Angel Gonzalez-Gay14, Javier Martín15 and Spanish GCA Group, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 3Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 4Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain, 5Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, 6Department of Rheumatology, Hospital Xeral-Calde, Lugo, Spain, 7Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 8Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 9Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 10Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 11Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, 12Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, 13Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 14Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 15Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: giant cell arteritis, phenotypes and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Vasculitis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis that primarily affects the aorta and external carotid arteries and their branches, leading to ischemic manifestations such as headaches or jaw claudication. Visual loss, commonly secondary to anterior ischemic optic neuropathy, represents the most severe complication. Polymyalgia rheumatica (PMR), characterised by aching and morning stiffness in the neck, shoulder and pelvic girdle, is present in up to 50% of patients. Less often, neurological symptoms, such as transient ischemic attacks and strokes, have been identified in GCA patients. The aim of the present study was to perform a stratified analysis of a published Immunochip to identify genetic factors contributing to the main clinical manifestations of GCA.

Methods: Data from an Immunochip performed on 763 Spanish GCA patients were stratified according to the presence/absence of PMR, jaw claudication, visual manifestations (transient visual loss including amaurosis fugax, permanent visual loss, or diplopia) and stroke. Allele frequencies were compared between the different subgroups of GCA patients and 1,517 unaffected controls, and between patients with and without the considered phenotypes. Logistic regression analyses adjusted by the 3 first principal components and sex were performed using an additive model.

Results: After genotyping and quality control, 132,117 genetic variants were analyzed in GCA patients showing PMR (n=318), jaw claudication (n=331), visual manifestations (n=228) or stroke (n=43). Several loci showed suggestive associations with the different clinical manifestations, specifically MAFB (a transcription factor involved in the monocyte-macrophage differentiation) was associated with jaw claudication (p=2.31×10-6, OR=1.57), KIR2DL1/KIR2DL4 (transmembrane glycoproteins playing an important role in the immune response regulation) appeared to be involved in PMR (p=5.26×10-6, OR=1.69), ADAMTSL3 (implicated in angiogenesis and up regulated in astrocytes from the optic nerve in patients with glaucoma) showed an association with the development of visual manifestations (p=9.57×10-6, OR=1.69), and SULT6B1 (a sulfotransferase which catalyzes the sulfonation of xenobiotics, hormones and neurotransmitters) was implicated in GCA-associated stroke (p=1.67×10-5, OR=2.68). In all cases, the analysis of GCA patients accordingly with the presence/absence of each clinical condition also reached statistical significance (p=0.025, p=3.89×10-3, p=4.94×10-3 and p=8.96×10-6, respectively).

Conclusion: Using a stratified large-scale analysis, we have identified four novel loci potentially involved in the development of the main clinical complications occurring in GCA patients.


Disclosure: A. Márquez, None; F. D. Carmona, None; M. C. Cid, None; J. Hernández-Rodríguez, None; R. Solans, None; M. Ramentol, None; S. Castañeda, None; J. A. Miranda-Filloy, None; I. C. Morado, None; J. Narváez, None; E. De Miguel, None; B. Sopeña, None; J. Monfort, None; M. J. Garcia-Villanueva, None; N. Ortego-Centeno, None; M. A. Gonzalez-Gay, None; J. Martín, None.

To cite this abstract in AMA style:

Márquez A, Carmona FD, Cid MC, Hernández-Rodríguez J, Solans R, Ramentol M, Castañeda S, Miranda-Filloy JA, Morado IC, Narváez J, De Miguel E, Sopeña B, Monfort J, Garcia-Villanueva MJ, Ortego-Centeno N, Gonzalez-Gay MA, Martín J. Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-genetic-factors-associated-with-clinical-manifestations-of-giant-cell-arteritis-through-a-stratified-large-scale-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-genetic-factors-associated-with-clinical-manifestations-of-giant-cell-arteritis-through-a-stratified-large-scale-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology